Corporate Banner
Satellite Banner
Pharma Outsourcing
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Joint Clinical Trials Office Launched

Published: Friday, February 01, 2013
Last Updated: Friday, February 01, 2013
Bookmark and Share
Weill Cornell Medical College and NewYork-Presbyterian Hospital launched the new Joint Clinical Trials Office at NewYork-Presbyterian/Weill Cornell Medical Center and Weill Cornell Medical College.

"The goal is to partner and invest in support of developing and expanding high-impact clinical trials that synergize with our missions of patient care, clinical and translational research and medical education," said Dr. John Leonard, director of the Office and associate dean for clinical research, the Richard T. Silver Distinguished Professor of Hematology and Medical Oncology and professor of medicine at Weill Cornell.

The new Joint Clinical Trials Office at Weill Cornell and NewYork-Presbyterian will also collaborate with Weill Cornell's Clinical and Translational Science Center in support of investigators who are testing new treatments and providing new insights into disease. What Weill Cornell and NewYork-Presbyterian wants accomplish, Dr. Leonard said, is to increase the volume, quality and impact of clinical trials at all departments at the medical center while maximizing efficiencies and ensuring compliance.

"If we want to be first-rate in clinical research," he said, "we need to have an infrastructure and provide support that is consistent with our goals."

And that is to be the premier place for clinical trials designed by faculty and in collaboration with industry.

"There are a tremendous number of drugs out there, and we want our investigators to be playing a leadership role," Dr. Leonard said. "Industry is interested in institutions that can contribute both patients and expertise to the enterprise. We want to continue to develop and assist physician-scientists who are leaders in the field, who are innovative in their ways in bringing therapeutics forward. That is what industry wants and needs."

Increasingly, academic medical centers and industry are forging mutually beneficial partnerships, changing the paradigm of the two arms of biomedical research working independently of each other to achieve the same ends. A recent article in Nature Biotechnology notes that these partnerships produce a greater wealth of understanding about basic biology and disease pathogenesis that can result in more effective and safer drugs and treatments. Academia's strength in research and study design can further buttress industry's research and development programs that have in many cases thinned as a result of downsizing.

Weill Cornell and NewYork-Presbyterian are currently recruiting for top leadership positions in the office and establishing a steering committee to provide guidance and oversight, Dr. Leonard said. He expects the activities of the office to ramp up in earnest during the first half of 2013.

"Clinical trials are part of the culture of the institutions, and our faculty, staff and patients really want and expect to be part of clinical trials in every area of the Medical College," he said. "We hope that everybody involved will in one way or another contribute to this important enterprise."


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,200+ scientific posters on ePosters
  • More than 4,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Cocaine Vaccine Passes Key Testing Hurdle
New anti-cocaine vaccine research shows drug can't reach the brain, human clinical trials on the horizon.
Monday, May 13, 2013
Scientific News
What Makes a Good Scientist?
It’s the journey, not just the destination that counts as a scientist when conducting research.
Investigational Malaria Vaccine Protects Healthy U.S. Adults
Researchers at NIH have found that the malaria vaccine protected a small number of healthy, malaria-naïve adults in the U.S. from infection for more than one year after immunization.
AACR 2016: Cancer Immunotherapy and Beyond
At this year's meeting there was a palpable buzz around subjects ranging from microbiomics to the tumor microenvironment and cancer vaccines, big data to in vitro and in vivo modeling and drug delivery (to name just a few).
New Database for Sharing MS Clinical Trial Data
A new database containing nearly 2500 patient records from the placebo arms of nine multiple sclerosis (MS) clinical trials is now available for research by qualified investigators.
Study Finds Factors That May Influence Influenza Vaccine Effectiveness
Researchers at NIH have suggested that the long-held approach to predicting seasonal influenza vaccine effectiveness may need to be revisited.
BMS’s Opdivo Clinical Trial Shows Promise
Safety profile of the combination regimen from CheckMate -069 was consistent with previously reported studies and adverse events were managed using established safety algorithms.
Treatment of Common Prostate Cancer
Researchers at UTSW have found that the prostate cancer treatments suppress immune response and may promote relapse.
Cancer Drug Could Treat Blood Vessel Deformities
A drug currently being trialled in cancer patients could also be used to treat an often incurable condition that can cause painful blood vessel overgrowths inside the skin.
Structure of Crucial Enzyme Identified
Researchers at UTSW have determined the atomic structure of an enzyme that plays an essential role in cell division and better treatment of cancer.
New Immunotherapy Trial for Type 1 Diabetes
The search for a treatment for Type 1 diabetes (T1D) - which affects over 400,000 people in the UK – will be stepped up with the start of a new phase one clinical trial at Guy’s Hospital in London.
Scroll Up
Scroll Down
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,200+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!